TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve

Xiuning Le et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.